Superworth

Skye Bioscience EPS SKYE

Diluted earnings per share by quarter and over the last twelve months, from 2012.

Last 12 months, to Jun 30, 2026
−$10.16
Latest quarter, Q2 FY26
−$2.16
Fiscal year 2025
−$11.20

Skye Bioscience's earnings per share was −$10.16 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$2.16.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$11.20n/a
FY2024−$5.76n/a
FY2023−$45.60n/a
FY2022−$79.68n/a
FY2021−$60.00n/a
FY2020−$80.00n/a
FY2019−$80.00n/a
FY2018−$360.00n/a
FY2017−$320.00n/a
FY2016−$380.00n/a
FY2015−$600.00n/a
FY2014n/an/a
FY2013n/an/a
FY2013n/an/a
FY2012$0.00n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$2.16n/a−$10.16
Q1 FY26−$2.56n/a−$11.52
Q4 FY25−$2.88n/a−$11.20
Q3 FY25−$2.56n/a−$10.24
Q2 FY25−$3.52n/a−$8.48
Q1 FY25−$2.24n/a−$6.56
Q4 FY24−$1.92n/a−$5.76
Q3 FY24−$0.80n/a−$6.72
Q2 FY24−$1.60n/a−$31.28
Q1 FY24−$1.44n/a−$36.08
Q4 FY23−$2.88n/a−$45.60
Q3 FY23−$25.36n/a−$69.76

Against its peers

Companies in Healthcare nearest Skye Bioscience's size, closest first, today.

CompanyEPS, 12 monthsGrowth
SKYESkye Bioscience−$10.16
NEPHNephros$0.16+33% a year
ATNMActinium Pharmaceuticals$0.36
APTAlpha Pro Tech$0.41+24% a year
SPROSpero Therapeutics$0.11
Peer median$0.26

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Skye Bioscience

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.